{
  "id": "517138d98ed59a060a000003",
  "type": "summary",
  "question": "How does ranolazine affect calcium handling in the heart",
  "ideal_answer": "Ranolazine has only a small effect on the basal calcium current, while it greatly affects whole cell calcium current when facilitated by beta-adrenoceptor or histamine receptor activation.\nRanolazine is a novel agent that inhibits the late sodium current thereby reducing cellular sodium and calcium overload.\nRanolazine reduces Ca2+ overload and LV mechanical dysfunction during ischemia/reperfusion.\nranolazine decreases  I(Na,L)-induced dysregulation of calcium cycling that contributes to the antiarrhythmic actions of this agent.\nranolazine desensitizes Ca(2+)-dependent RyR2 activation, and inhibits Ca(i) oscillations.\nranolazine ameliorates the Ca(2+) response and cross-bridge kinetics of cardiac myofilaments.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/21741479",
    "http://www.ncbi.nlm.nih.gov/pubmed/17027025",
    "http://www.ncbi.nlm.nih.gov/pubmed/18439620",
    "http://www.ncbi.nlm.nih.gov/pubmed/23247666",
    "http://www.ncbi.nlm.nih.gov/pubmed/17220471",
    "http://www.ncbi.nlm.nih.gov/pubmed/22879384",
    "http://www.ncbi.nlm.nih.gov/pubmed/22245792",
    "http://www.ncbi.nlm.nih.gov/pubmed/19675298",
    "http://www.ncbi.nlm.nih.gov/pubmed/23271797",
    "http://www.ncbi.nlm.nih.gov/pubmed/22709755",
    "http://www.ncbi.nlm.nih.gov/pubmed/22343711",
    "http://www.ncbi.nlm.nih.gov/pubmed/8735623",
    "http://www.ncbi.nlm.nih.gov/pubmed/16781216",
    "http://www.ncbi.nlm.nih.gov/pubmed/16775092",
    "http://www.ncbi.nlm.nih.gov/pubmed/20924097",
    "http://www.ncbi.nlm.nih.gov/pubmed/23596505"
  ],
  "snippets": [
    {
      "text": "Ranolazine and lidocaine (10 \u03bcM) similarly reduced Ca2+i overload and improved left ventricle work recovery in whole-heart models of IR injury or exposure to ouabain (80 \u03bcM).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22879384",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine (10 \u03bcM), but not lidocaine (10 \u03bcM), reduced RM NCX1.1-mediated Ca2+i overload in ventricular myocytes.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22879384",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Blockade of the late inward sodium current, late I(Na), offers another target for the treatment of ischemia. Blockade of late I(Na) reduces the sodium and calcium overload that follows ischemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23247666",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine, a late I(Na) inhibitor, has been shown to provide both anti-anginal and anti-ischemic benefits without significant alterations in the heart rate and blood pressure in patients with stable coronary artery disease.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23247666",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine is a new antianginal drug that reduces intracellular sodium and calcium accumulation during ischemia, thus potentially limiting myocardial ischemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22709755",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Detergent extracted fiber bundles from DOCA-salt hearts demonstrated increased myofilament response to Ca(2+) with glutathionylation of myosin binding protein C. Treatment with ranolazine ameliorated the Ca(2+) response and cross-bridge kinetics.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22343711",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ran reduces P(o) of RyR2, desensitizes Ca(2+)-dependent RyR2 activation, and inhibits Ca(i) oscillations,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22245792",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine may provide functional protection of the heart during IR injury by reducing cCa2+ and mCa2+ loading secondary to its effect to block the late Na+ current.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/21741479",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine is a novel antianginal medication that acts by ameliorating disturbed sodium and calcium homeostasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924097",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "By preventing myocyte sodium and calcium overload, ranolazine also have potential beneficial effects on myocardial function.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20924097",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Reduction by RAN of I(Na,L)-induced dysregulation of calcium cycling could contribute to the antiarrhythmic actions of this agent in both reentrant and triggered arrhythmias.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19675298",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Moreover, in rabbit myocytes the increases in late I(Na), [Na(+)](i) and [Ca(2+)](i) caused by ATX-II, were significantly blunted by ranolazine. These results suggest that ranolazine may be of therapeutic benefit in conditions of diastolic dysfunction due to elevated [Na(+)](i) and diastolic [Ca(2+)](i).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18439620",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine is a selective inhibitor of the late sodium current relative to peak sodium channel current, and via this mechanism, it may decrease sodium-dependent intracellular calcium overload during ischemia and reperfusion.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17220471",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "he beneficial effects of ranolazine in reducing Ca2+ overload and LV mechanical dysfunction during ischemia/reperfusion is consistent with the inhibition of late INa mechanism of action.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17027025",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine is a novel agent that inhibits the late sodium current thereby reducing cellular sodium and calcium overload",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16781216",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine selectively inhibits late I(Na), reduces [Na(+)](i)-dependent calcium overload and attenuates the abnormalities of ventricular repolarisation and contractility that are associated with ischaemia/reperfusion and heart failure.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16775092",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "The results indicate that ranolazine, at concentrations which have significantly beneficial effects during ischaemic episodes, only greatly affects whole cell calcium current when facilitated by beta-adrenoceptor or histamine receptor activation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8735623",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    },
    {
      "text": "Ranolazine had only a small effect on the basal calcium current",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/8735623",
      "beginSection": "sections.0",
      "endSection": "sections.0"
    }
  ],
  "concepts": [
    "http://www.uniprot.org/uniprot/CCAMK_ORYSJ",
    "http://www.uniprot.org/uniprot/CCAMK_LOTJA",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D002118",
    "http://www.disease-ontology.org/api/metadata/DOID:114",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006331",
    "http://www.uniprot.org/uniprot/CCAMK_PEA",
    "http://www.biosemantics.org/jochem#4277675",
    "http://www.biosemantics.org/jochem#4268168",
    "http://www.biosemantics.org/jochem#4071295",
    "http://www.biosemantics.org/jochem#4000018",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D006321",
    "http://www.nlm.nih.gov/cgi/mesh/2012/MB_cgi?field=uid&exact=Find+Exact+Term&term=D009206",
    "http://www.biosemantics.org/jochem#4260677",
    "http://www.biosemantics.org/jochem#4202863",
    "http://www.biosemantics.org/jochem#4202864",
    "http://www.uniprot.org/uniprot/CCAMK_LILLO"
  ]
}